PL352232A1 - Il-8 receptor antagonists - Google Patents
Il-8 receptor antagonistsInfo
- Publication number
- PL352232A1 PL352232A1 PL00352232A PL35223200A PL352232A1 PL 352232 A1 PL352232 A1 PL 352232A1 PL 00352232 A PL00352232 A PL 00352232A PL 35223200 A PL35223200 A PL 35223200A PL 352232 A1 PL352232 A1 PL 352232A1
- Authority
- PL
- Poland
- Prior art keywords
- receptor antagonists
- antagonists
- receptor
- Prior art date
Links
- 102000010681 interleukin-8 receptors Human genes 0.000 title 1
- 108010038415 interleukin-8 receptors Proteins 0.000 title 1
- 239000002464 receptor antagonist Substances 0.000 title 1
- 229940044551 receptor antagonist Drugs 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Physical Education & Sports Medicine (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Biotechnology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pulmonology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Quinoline Compounds (AREA)
- Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
- Heterocyclic Compounds Containing Sulfur Atoms (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13967599P | 1999-06-16 | 1999-06-16 |
Publications (1)
Publication Number | Publication Date |
---|---|
PL352232A1 true PL352232A1 (en) | 2003-08-11 |
Family
ID=22487790
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL00352232A PL352232A1 (en) | 1999-06-16 | 2000-06-15 | Il-8 receptor antagonists |
Country Status (20)
Country | Link |
---|---|
EP (1) | EP1185261A4 (en) |
JP (1) | JP2003501459A (en) |
KR (1) | KR20020010709A (en) |
CN (1) | CN1355697A (en) |
AR (1) | AR030391A1 (en) |
AU (1) | AU766083B2 (en) |
BR (1) | BR0010802A (en) |
CA (1) | CA2377341A1 (en) |
CO (1) | CO5200760A1 (en) |
CZ (1) | CZ20014471A3 (en) |
HK (1) | HK1044483A1 (en) |
HU (1) | HUP0201571A3 (en) |
IL (1) | IL145761A0 (en) |
MX (1) | MXPA01013004A (en) |
NO (1) | NO20016053L (en) |
NZ (1) | NZ514695A (en) |
PL (1) | PL352232A1 (en) |
TR (1) | TR200103680T2 (en) |
WO (1) | WO2000076495A1 (en) |
ZA (1) | ZA200109479B (en) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7521479B2 (en) * | 2001-04-16 | 2009-04-21 | Panacea Pharmaceuticals, Inc. | Methods of treating prion disease in mammals |
GB0201882D0 (en) * | 2002-01-28 | 2002-03-13 | Novartis Ag | Organic compounds |
AU2003260280A1 (en) * | 2002-08-01 | 2004-02-23 | Neurosearch A/S | Compounds useful for the treatment of diseases responsive to antiangiogenetic therapy |
US7550499B2 (en) | 2004-05-12 | 2009-06-23 | Bristol-Myers Squibb Company | Urea antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions |
EP1745032B1 (en) * | 2004-05-12 | 2013-07-31 | Merck Sharp & Dohme Corp. | CXCR1 and CXCR2 chemokine antagonists |
TW200600492A (en) * | 2004-05-18 | 2006-01-01 | Achillion Pharmaceuticals Inc | Substituted aryl acylthioureas and related compounds; inhibitors of viral replication |
US7582673B2 (en) | 2004-10-21 | 2009-09-01 | High Point Pharmaceuticals, Llc | Bissulfonamide compounds as agonists of GalR1, compositions, and methods of use |
KR20070100894A (en) | 2005-01-19 | 2007-10-12 | 브리스톨-마이어스 스큅 컴퍼니 | 2-phenoxy-n-(1,3,4-thiadizol-2-yl)pyridin-3-amine derivatives and related compounds as p2y1 receptor inhibitors for the treatment of thromboembolic disorders |
WO2006089871A2 (en) * | 2005-02-23 | 2006-08-31 | Neurosearch A/S | Diphenylurea derivatives useful as erg channel openers for the treatment of cardiac arrhythmias |
EP1896466B1 (en) | 2005-06-27 | 2011-04-13 | Bristol-Myers Squibb Company | N-linked heterocyclic antagonists of p2y1 receptor useful in the treatment of thrombotic conditions |
DE602006020871D1 (en) | 2005-06-27 | 2011-05-05 | Bristol Myers Squibb Co | LINEAR UREA MIMETIC ANTAGONISTS OF THE P2Y1 RECEPTOR FOR THE TREATMENT OF THROMBOSELEIDES |
US7700620B2 (en) | 2005-06-27 | 2010-04-20 | Bristol-Myers Squibb Company | C-linked cyclic antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions |
WO2007002634A1 (en) | 2005-06-27 | 2007-01-04 | Bristol-Myers Squibb Company | Carbocycle and heterocycle antagonists of p2y1 receptor useful in the treatment of thrombotic conditions |
US7960569B2 (en) | 2006-10-17 | 2011-06-14 | Bristol-Myers Squibb Company | Indole antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions |
JP2008184403A (en) * | 2007-01-29 | 2008-08-14 | Japan Health Science Foundation | New hepatitis c virus inhibitor |
KR100982661B1 (en) * | 2008-04-22 | 2010-09-17 | 전남대학교산학협력단 | Pharmaceutical composition for the prevention and treatment of malaria containing a compound that inhibits plasmincin II activity as an active ingredient and a method for treating malaria using the same |
KR100970940B1 (en) * | 2010-05-03 | 2010-07-20 | 전남대학교산학협력단 | Pharmaceutical composition for preventing and treating malaria comprising compounds that inhibit Plasmepsin II activity and the method of treating malaria using thereof |
US10093617B1 (en) * | 2015-10-30 | 2018-10-09 | Sumitomo Chemical Company, Limited | Method for producing 2-amino-4-substituted phenol |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ZA921120B (en) * | 1991-02-19 | 1993-01-27 | Smithkline Beecham Corp | Cytokine inhibitors |
JPH11503110A (en) * | 1995-02-17 | 1999-03-23 | スミスクライン・ビーチャム・コーポレイション | IL-8 receptor antagonist |
WO2000016768A1 (en) * | 1998-09-18 | 2000-03-30 | Smithkline Beecham Corporation | Cxcr2 inhibitors and pmn adhesion and t-cell chemotaxis |
-
2000
- 2000-06-13 CO CO00043844A patent/CO5200760A1/en not_active Application Discontinuation
- 2000-06-14 AR ARP000102923A patent/AR030391A1/en not_active Application Discontinuation
- 2000-06-15 CN CN00809045A patent/CN1355697A/en active Pending
- 2000-06-15 WO PCT/US2000/016499 patent/WO2000076495A1/en not_active Application Discontinuation
- 2000-06-15 PL PL00352232A patent/PL352232A1/en not_active Application Discontinuation
- 2000-06-15 AU AU57413/00A patent/AU766083B2/en not_active Ceased
- 2000-06-15 EP EP00942843A patent/EP1185261A4/en not_active Withdrawn
- 2000-06-15 NZ NZ514695A patent/NZ514695A/en unknown
- 2000-06-15 CA CA002377341A patent/CA2377341A1/en not_active Abandoned
- 2000-06-15 KR KR1020017016142A patent/KR20020010709A/en not_active Application Discontinuation
- 2000-06-15 JP JP2001502828A patent/JP2003501459A/en not_active Withdrawn
- 2000-06-15 TR TR2001/03680T patent/TR200103680T2/en unknown
- 2000-06-15 CZ CZ20014471A patent/CZ20014471A3/en unknown
- 2000-06-15 MX MXPA01013004A patent/MXPA01013004A/en unknown
- 2000-06-15 IL IL14576100A patent/IL145761A0/en unknown
- 2000-06-15 BR BR0010802-2A patent/BR0010802A/en not_active IP Right Cessation
- 2000-06-15 HU HU0201571A patent/HUP0201571A3/en unknown
-
2001
- 2001-11-16 ZA ZA200109479A patent/ZA200109479B/en unknown
- 2001-12-11 NO NO20016053A patent/NO20016053L/en not_active Application Discontinuation
-
2002
- 2002-08-22 HK HK02106188.7A patent/HK1044483A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
NZ514695A (en) | 2004-05-28 |
CN1355697A (en) | 2002-06-26 |
AU766083B2 (en) | 2003-10-09 |
HK1044483A1 (en) | 2002-10-25 |
ZA200109479B (en) | 2002-11-18 |
EP1185261A4 (en) | 2004-02-25 |
KR20020010709A (en) | 2002-02-04 |
BR0010802A (en) | 2002-02-19 |
IL145761A0 (en) | 2002-07-25 |
NO20016053D0 (en) | 2001-12-11 |
HUP0201571A3 (en) | 2002-11-28 |
TR200103680T2 (en) | 2002-07-22 |
AR030391A1 (en) | 2003-08-20 |
AU5741300A (en) | 2001-01-02 |
EP1185261A1 (en) | 2002-03-13 |
NO20016053L (en) | 2001-12-11 |
HUP0201571A2 (en) | 2002-08-28 |
WO2000076495A1 (en) | 2000-12-21 |
CA2377341A1 (en) | 2000-12-21 |
MXPA01013004A (en) | 2002-07-30 |
CO5200760A1 (en) | 2002-09-27 |
CZ20014471A3 (en) | 2002-08-14 |
JP2003501459A (en) | 2003-01-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL145761A0 (en) | Il-8 receptor antagonists | |
DZ3309A1 (en) | Il-8 receptor antagonists | |
AU4560601A (en) | Il-8 receptor antagonists | |
IL145762A0 (en) | Il-8 receptor antagonists | |
IL146046A0 (en) | Il-8 receptor antagonists | |
AP2002002599A0 (en) | Il-8 receptor antagonists | |
PL351947A1 (en) | Il-8 receptor antagonists | |
EP1047424A4 (en) | Il-8 receptor antagonists | |
EP1039903A4 (en) | Il-8 receptor antagonists | |
HK1044717A1 (en) | Il-8 receptor antagonists | |
EP1261329A4 (en) | Il-8 receptor antagonists | |
HK1044475A1 (en) | Il-8 receptor antagonists | |
IL146515A0 (en) | Il-8 receptor antagonists | |
PL352218A1 (en) | Il-8 receptor antagonists | |
PL346178A1 (en) | Il-8 receptor antagonists | |
EP1237548A4 (en) | Il-8 receptor antagonists | |
ZA985813B (en) | IL-8 receptor antagonists | |
ZA985975B (en) | IL-8 receptor antagonists | |
EP1121360A4 (en) | Il-8 receptor antagonists | |
EP1087661A4 (en) | Il-8 receptor antagonists |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
REFS | Decisions on refusal to grant patents (taken after the publication of the particulars of the applications) |